FOSUN WANBANG (JIANGSU) PHARMACEUTICAL GROUP CO.,
PharmaFOSUN WANBANG (JIANGSU) PHARMACEUTICAL GROUP CO., is a pharmaceutical company with 3 FDA-approved products.
FOSUN WANBANG (JIANGSU) PHARMACEUTICAL GROUP CO.,'s Key Drugs
FOSUN WANBANG (JIANGSU) PHARMACEUTICAL GROUP CO.,'s core commercial portfolio centers on SITAGLIPTIN AND METFORMIN HYDROCHLORIDE — its most strategically important drugs approved in the last 15 years.
FOSUN WANBANG (JIANGSU) PHARMACEUTICAL GROUP CO.,'s Recent FDA Approvals
New NDA/BLA approvals for FOSUN WANBANG (JIANGSU) PHARMACEUTICAL GROUP CO., over the last two years — novel drugs only, excluding generics and label supplements.
FOSUN WANBANG (JIANGSU) PHARMACEUTICAL GROUP CO.,'s Therapeutic Areas
Disease areas where FOSUN WANBANG (JIANGSU) PHARMACEUTICAL GROUP CO., has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
FOSUN WANBANG (JIANGSU) PHARMACEUTICAL GROUP CO., Pipeline Snapshot
Active clinical trials for FOSUN WANBANG (JIANGSU) PHARMACEUTICAL GROUP CO., across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SITAGLIPTIN AND METFORMIN HYDROCHLORIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- -
- Latest
- -
- Applications
- 3